Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bu-Shu Xu
Observed names:
B. Xu,
B.Q. Xu,
Bu-shu Xu,
Bushu Xu,
Bu‐Shu Xu
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
Cancer Hospital of Chinese Academy of Medical Sciences,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0009-0001-0889-6169
Observed ORCID:
0009-0001-0889-6169
OpenAlex ID:
A5088393463
Tumor metastasis: Mechanistic insights and therapeutic interventions
2021
·
Mengmeng Liu
, Jing Yang
, et al.
·
MedComm
·
134
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
2021
·
Yi Que
, Xiao-Long Zhang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
111
PDF
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis
2017
·
Yi Que
, Wei Xiao
, et al.
·
Journal of Cancer
·
104
PDF
Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma
2023
·
Qiuzhong Pan
, Desheng Weng
, et al.
·
Cell Reports Medicine
·
73
PDF
Haemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of the TNM Staging System in Nasopharyngeal Carcinoma: Development and Validation in 3237 Patients from a Single Institution
2013
·
H. Chang
, J. Gao
, et al.
·
Clinical Oncology
·
55
FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma
2024
·
Wei Xiao
, Liping Xu
, et al.
·
Cancer Gene Therapy
·
40
PDF
Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial
2023
·
Bushu Xu
, Qiuzhong Pan
, et al.
·
EClinicalMedicine
·
37
PDF
Chimeric antigen receptor‐modified T‐cell therapy for platelet‐derived growth factor receptor α‐positive rhabdomyosarcoma
2020
·
Wei Xiao
, Jinghua Wang
, et al.
·
Cancer
·
28
ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma
2019
·
Bu-Shu Xu
, Huo-Ying Chen
, et al.
·
Oncogene
·
28
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma
2022
·
Xi-zhi Wen
, Qiu-zhong Pan
, et al.
·
Cancer Chemotherapy and Pharmacology
·
23
Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade
2023
·
Dong-Chun Hong
, Jing Yang
, et al.
·
Clinical Cancer Research
·
21
PDF
The Impact of Unplanned Excision on the Outcomes of Patients With Soft Tissue Sarcoma of the Trunk and Extremity: A Propensity Score Matching Analysis
2021
·
Yao Liang
, Tian-Hui Guo
, et al.
·
Frontiers in Oncology
·
20
PDF
Targeting KIFC1 Promotes Senescence in Soft Tissue Sarcoma via FXR1‐Dependent Regulation of MAD2L1 mRNA Stability
2024
·
Xiu‐Xia Lu
, Yi Que
, et al.
·
Advanced Science
·
11
PDF
Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients
2019
·
Wei Xiao
, Yao Liang
, et al.
·
Journal of Cancer
·
8
PDF
Phase I clinical trial to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of NY-ESO-1–specific TCR T-cells (TAEST16001) in HLA-A*02:01 patients with advanced soft tissue sarcoma.
2022
·
Xing Zhang
, Desheng Weng
, et al.
·
Journal of Clinical Oncology
·
7
Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.
2024
·
Jiayong Liu
, Tian Gao
, et al.
·
Journal of Clinical Oncology
·
5
New nomograms to predict overall and cancer‐specific survival of angiosarcoma
2021
·
Yuan‐Yuan Liu
, Bu‐Shu Xu
, et al.
·
Cancer Medicine
·
5
PDF
The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience
2025
·
Qiyan Cai
, Bushu Xu
, et al.
·
BMC Cancer
·
3
PDF
A phase II study of surufatinib in patients with osteosarcoma and soft tissue sarcoma who have experienced treatment failure with standard chemotherapy.
2023
·
Xing Zhang
, Qiuzhong Pan
, et al.
·
Journal of Clinical Oncology
·
3
Novel Location-Grading-Node-Metastasis Staging System in Patients With Head and Neck Soft Tissue Sarcoma
2025
·
Dingfu Du
, Shaojun Wu
, et al.
·
Journal of Otolaryngology - Head and Neck Surgery
·
2
A phase II clinical trial of chidamide in combination with toripalimab in patients with advanced soft tissue sarcoma.
2023
·
Xing Zhang
, Ruiqing Peng
, et al.
·
Journal of Clinical Oncology
·
2
A phase II, multicenter trial of the combination of chidamide and toripalimab in patients with advanced soft tissue sarcoma: Efficacy updates.
2025
·
Xing Zhang
, Ruiqing Peng
, et al.
·
Journal of Clinical Oncology
·
1
Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis.
2024
·
Xing Zhang
, Qiuzhong Pan
, et al.
·
Journal of Clinical Oncology
·
1
PDF
The inflammatory‐nutritional score and nomogram for R0 resected head and neck soft tissue sarcoma
2023
·
Bushu Xu
, Haibo Qiu
, et al.
·
Oral Diseases
·
1
PDF
Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
2016
·
J. Huang
, Y. Liu
, et al.
·
Annals of Oncology
·
1
Show more works
View as search
Works count:
88
Citation count:
724
H-index:
12
I10-index:
13
Year
Topic
Type